Repare Therapeutics Inc.
RPTX
$1.42
$0.000.00%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -98.90% | 4.58% | 18.19% | -58.79% | -28.62% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -98.90% | 4.58% | 18.19% | -58.79% | -28.62% |
| Cost of Revenue | -95.28% | 1.05% | -94.95% | -91.43% | -88.22% |
| Gross Profit | -99.53% | 5.82% | 186.46% | 37.28% | 456.31% |
| SG&A Expenses | -13.77% | -10.89% | -2.77% | 1.15% | 4.59% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.73% | -12.99% | -1.57% | 2.90% | 7.55% |
| Operating Income | -85.05% | 20.72% | 12.17% | -1,502.87% | -259.97% |
| Income Before Tax | -118.23% | 19.32% | 10.39% | -546.89% | -452.98% |
| Income Tax Expenses | 109.55% | 115.35% | -70.12% | -169.49% | -166.04% |
| Earnings from Continuing Operations | -179.90% | 9.71% | 13.73% | -2,121.82% | -56.32% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -179.90% | 9.71% | 13.73% | -2,121.82% | -56.32% |
| EBIT | -85.05% | 20.72% | 12.17% | -1,502.87% | -259.97% |
| EBITDA | -86.68% | 21.05% | 12.46% | -1,176.37% | -287.24% |
| EPS Basic | -177.18% | 10.59% | 14.41% | -2,216.14% | -56.14% |
| Normalized Basic EPS | -108.22% | 21.43% | 12.72% | -541.11% | -453.40% |
| EPS Diluted | -174.67% | 10.07% | 13.95% | -921.20% | -39.74% |
| Normalized Diluted EPS | -106.24% | 20.89% | 12.11% | -656.97% | -309.26% |
| Average Basic Shares Outstanding | 0.85% | 0.75% | 0.63% | 0.52% | 0.42% |
| Average Diluted Shares Outstanding | -0.21% | 1.82% | 1.69% | 0.25% | 0.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |